AIMP1 antibody

Catalog No. ABIN636614

Product Details anti-AIMP1 Antibody

Target: AIMP1 (Aminoacyl tRNA Synthetase Complex-Interacting Multifunctional Protein 1 (AIMP1))

Reactivity: Human

Host: Goat

Clonality: Polyclonal

Conjugate: This AIMP1 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Blocking Antibody (Inhibition)

Purification: Purified

Immunogen: EMAP II antibody was raised in goat using highly pure recombinant human EMAP-II as the immunogen.

Application Details

Application Notes: Optimal conditions should be determined byt he investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized from PBS, pH 7.2.

Handling Advice: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Storage: 4 °C/-20 °C

Storage Comment: Store at -20 °C until reconstitution. Following reconstitution product may be stored at 4 °C in the short term. For long term storage aliquot and freeze at -20 °C.

Target Details for AIMP1

Target: AIMP1 (Aminoacyl tRNA Synthetase Complex-Interacting Multifunctional Protein 1 (AIMP1))

Alternative Name: EMAP II (AIMP1 Products)

Synonyms: EMAP2 antibody, EMAPII antibody, HLD3 antibody, SCYE1 antibody, p43 antibody, wu:fa95a05 antibody, zgc:154081 antibody, AIMP1 antibody, 9830137A06Rik antibody, AIMP1/p43 antibody, Emap2 antibody, Scye1 antibody, scye1 antibody, aminoacyl tRNA synthetase complex interacting multifunctional protein 1 antibody, aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 antibody, aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 S homeolog antibody, AIMP1 antibody, aimp1 antibody, Aimp1 antibody, aimp1.S antibody

Background: EMAP-II is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.

Molecular Weight: 18.3 kDa (predicted detection band MW)